One thing to keep in mind is that the value of NGIO would increase significantly if and when they do have traditional solid partnership with Merck. They aren’t there yet. At that point, Merck invests into the partnership, not by only supplying to Keytruda for a study, but with a true commitment to NuGenerex. An up front payment, paying for a Phase III, milestone, etc etc. And that could happen as soon as the current open label study shows efficacy.